DOI:
10.1055/s-00000017
Experimental and Clinical Endocrinology & Diabetes
LinksClose Window
References
Yamada K, Nakayama H, Yoshinobu S. et al.
Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring.
J Diabetes Investig 2015;
6: 699-707
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.